hqygs
2019-10-09
$Viela Bio(VIE)$
Viela Bio今日与三菱田边制药公司展开战略合作,获得3000万美元授权许可费用于在日本和其他亚洲地区开发,用于自身免疫性疾病的英比利珠单抗并将其商业化,英比利珠单抗治疗视神经脊髓炎,已经被FDA批准,基于迄今为止最大的视神经脊髓炎单疗法研究结果,FDA授予inebilizumab此项突破性疗法资格认定
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
9
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":931803373,"tweetId":"931803373","gmtCreate":1570635502892,"gmtModify":1704721044848,"author":{"id":3481891351558811,"authorId":3481891351558811,"authorIdStr":"3481891351558811","name":"hqygs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><span><span><a href=\"https://laohu8.com/S/VIE\">$Viela Bio(VIE)$</a></span></span> <span><span></span></span><span> </span><span>Viela Bio今日与三菱田边制药公司展开战略合作,获得3000万美元授权许可费用于在日本和其他亚洲地区开发,用于自身免疫性疾病的英比利珠单抗并将其商业化,英比利珠单抗治疗视神经脊髓炎,已经被FDA批准,基于迄今为止最大的视神经脊髓炎单疗法研究结果,FDA授予inebilizumab此项突破性疗法资格认定</span></body></html>","htmlText":"<html><head></head><body><span><span><a href=\"https://laohu8.com/S/VIE\">$Viela Bio(VIE)$</a></span></span> <span><span></span></span><span> </span><span>Viela Bio今日与三菱田边制药公司展开战略合作,获得3000万美元授权许可费用于在日本和其他亚洲地区开发,用于自身免疫性疾病的英比利珠单抗并将其商业化,英比利珠单抗治疗视神经脊髓炎,已经被FDA批准,基于迄今为止最大的视神经脊髓炎单疗法研究结果,FDA授予inebilizumab此项突破性疗法资格认定</span></body></html>","text":"$Viela Bio(VIE)$ Viela Bio今日与三菱田边制药公司展开战略合作,获得3000万美元授权许可费用于在日本和其他亚洲地区开发,用于自身免疫性疾病的英比利珠单抗并将其商业化,英比利珠单抗治疗视神经脊髓炎,已经被FDA批准,基于迄今为止最大的视神经脊髓炎单疗法研究结果,FDA授予inebilizumab此项突破性疗法资格认定","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/931803373","repostId":0,"isVote":1,"tweetType":1,"viewCount":2324,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VIE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":285,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/931803373"}
精彩评论